Issued patents: USA #6,531,578 and 7,198,904; EU #EP1012605 and EP1412471; and Japan #H10-542722 and 5048207;
Patentable know-how: (a) production, isolation, and characterization of microvesicle-associated iNOS by our proprietary 5B2 cell line as positive control for IVD tests; (b) production, isolation, and characterization of normal microvesicles devoid of iNOS as negative control for IVD tests; (c) formulation of the positive and negative control components of the plasma iNOS IVD test; (d) production, isolation, and characterization of humanized anti-MV-A iNOS mAb as an API by our proprietary genetically engineered CHO cell line; (e) formulation of aSeptiMab as a Drug Product; and (f) a “Use Patent” for aSeptiMab to treat sepsis.
Trade secrets: proprietary hybridoma cell lines that produce the mAbs used in the IVD tests; our proprietary 5B2 cell line that produces microvesicle-associated iNOS; our proprietary genetically engineered CHO cell line that expresses the humanized anti-MV-A iNOS mAb; our proprietary purification process of the humanized anti-MV-A iNOS mAb; and our proprietary cell culture based efficacy assay for aSeptiMab.